Explore association of genes in PDL1/PD1 pathway to radiotherapy survival benefit based on interaction model strategy

Table 2 Associations of clinical variables with OS in METABRIC (total N = 1902)

		N	%	HR (95%CI)	P
Radiotherapy^a	No	765	59.78	1.000
	Yes	1137	40.22	0.883(0.762,1.023)	0.097
Chemotherapy	No	1506	79.18	1.000
	Yes	396	20.82	1.158(0.930,1.44)	0.198
Age^a	< 60	841	44.22	1.000
	≥ 60	1061	55.78	1.988(1.736,2.276)	< 0.001
Hormone therapy	No	728	38.28	1.000
	Yes	1174	61.72	0.942(0.808,1.099)	0.345
Surgery type^a	Conserving	755	40.14	1.000
	Mastectomy	1126	59.86	0.773(0.664,0.901)	0.002
Laterality	Left	935	52.03	1.000
	Right	862	47.97	0.948(0.841,1.068)	0.394
Grade	G1	164	8.96	1.000
	G2	740	40.42	0.861(0.669,1.107)	0.623
	G3	927	50.63	0.904(0.785,1.41)	0.195
ER status^a	Negative	444	23.34	1.000
	Positive	1458	76.66	0.740(0.590,0.929)	0.010
PR status	Negative	894	47.00	1.000
	Positive	1008	53.00	0.948(0.820,1.097)	0.411
HER2^a	Negative	1666	87.59	1.000
	Positive	236	12.41	1.322(1.076,1.624)	0.006
Menopausal status	Peri	411	21.61	1.000
	Post	1491	78.39	1.142(0.924,1.412)	0.254
Molecular subtypes^a	lumA	678	35.76	1.000
	Claudin-low	198	10.44	0.854(0.650,1.121)	0.255
	her2	220	11.60	1.179(0.929,1.500)	0.176
	Basal	199	10.50	1.132(0.851,1.507)	0.395
	lumB	461	24.31	1.350(1.156,1.576)	< 0.001
	Normal	140	7.38	1.263(0.983,1.621)	0.054
Tumor size (cm) ^a	< 2	591	31.39	1.000
	≥ 2	1292	68.61	1.270(1.087,1.484)	0.003
Lymph nodes^a	0	991	52.10	1.000
	≥ 1	911	47.90	1.363(1.161,1.600)	< 0.001
Pathological stage^a	I	478	34.09	0.798(0.660,0.965)	0.020
	II	800	57.06	1.000
	III/IV	124	8.84	1.554( 1.274,1.895)	< 0.001

^aClinical variables that were left after fast backward multivariate COX regression

ISSN: 1748-717X